Sounds just like you do not know what you are writing, because you mix generics and NDA to each other.
Selling NDA drug is exactly what you are describing, because you have to make the market. You are selling something new physicians don't yet know. You have to show how your new treatment is better than the old ones. You have to do this to every single physician.
Selling generics is a totally different ball game. Someone has already made the market. You do not need to tell everyone why it is better in treating patients. You need to be commercially better and it's something very much different. If you have been to this business, you must understand this clearly.
IPCI should start making and selling metformin and levetiracetam right now on their own and expand this as soon as possible. Only a product that does exist, can be sold. Now they just sit back and wait someone to come and buy. This does not work.
For super tiny ipci even a small sales internal organization would imply at least 12 months before hitting the market and a new shares dilution to finance the initial costs.
Ipci needs to concentrate on tech and NDAs via the licencing route. There stays the money.
Just having a look at big generics players performance should cause a big warning before considering any direct involvement. Usually price war destroys small players.
Wow thnx for the brilliant post Samsa! I still find it hard to believe that Odidi can't figure out what his longest serving core shareholders and the market masses have figured out.
If he can't get out of his head and into the game soon his science and the once great potential of this company is doomed.